Keyword: Evrenzo (roxadustat)
Because of the China COVID-19 epidemic, AstraZeneca pared its 2020 revenue forecast—and at a time when three key cancer meds missed their marks.
Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.
New FibroGen CEO and former Eli Lilly vet, Enrique Conterno, cleared some existing investor doubts about roxadustat's potential.
Enrique Conterno takes the helm at FibroGen as the company and partners prep for the launch of key drug roxadustat.
It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.
Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.
Thomas Neff founded FibroGen in 1993 and has led the company for decades. Now, it's searching for its next leader with his unexpected death.
Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.
As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.